HYDROCORTISONE VALERATE
Clinical safety rating: avoid
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
Corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects.
| Metabolism | Hepatic metabolism via cytochrome P450 enzymes (primarily CYP3A4). |
| Excretion | Renal (approximately 80% as metabolites, <1% unchanged), fecal/biliary (approximately 20% as metabolites) |
| Half-life | Terminal elimination half-life is approximately 2-3 hours for the parent drug; 18-36 hours for the active metabolites (clinical context: duration of action is prolonged due to local tissue retention and metabolite activity) |
| Protein binding | Approximately 90-95% bound to albumin and corticosteroid-binding globulin (CBG) |
| Volume of Distribution | 0.2-0.4 L/kg (indicating distribution primarily in extracellular fluid and limited tissue penetration) |
| Bioavailability | Topical: minimal systemic absorption (<5% in intact skin; up to 10-30% in inflamed or damaged skin); Oral: not applicable; Intralesional: nearly 100% at injection site |
| Onset of Action | Topical: 2-4 hours; Intralesional: 1-2 hours; Intra-articular: 2-4 hours |
| Duration of Action | Topical: 12-24 hours; Intralesional: 3-7 days; Intra-articular: 1-3 weeks |
| Molecular Weight | 432.55 |
Apply a thin film to affected area twice daily. Topical use only.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for topical use. |
| Liver impairment | No dose adjustment required for topical use. |
| Pediatric use | Apply sparingly to affected area once or twice daily in children; limit treatment duration to avoid systemic absorption. |
| Geriatric use | Use with caution; apply sparingly and avoid prolonged use due to increased risk of skin atrophy and systemic absorption. |
| 1st trimester | Topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Studies in animals have shown teratogenic effects with topical corticosteroids, but limited human data. Avoid large amounts or prolonged use. |
| 2nd trimester | Use with caution, short-term application over limited areas. Systemic absorption is minimal with topical use, but prolonged or extensive use may increase risk. |
| 3rd trimester | Use with caution; avoid use near term due to potential for fetal adrenal suppression. Short-term, small area use is preferred. |
Clinical note
CYP3A4 inducers (eg phenytoin) may decrease efficacy and inhibitors may increase effects Can cause hyperglycemia and adrenal suppression with prolonged use.
| FDA category | Positive |
| Placental transfer | Topical corticosteroids can be absorbed percutaneously and may cross the placenta. The degree of transfer is minimal with short-term, limited-area use, but prolonged or extensive use may lead to higher systemic levels and potential fetal effects. |
■ FDA Black Box Warning
None.
| Common Effects | adrenal insufficiency |
| Serious Effects |
Hypersensitivity to hydrocortisone or any component of the formulationUntreated bacterial, fungal, or viral skin infectionsPerioral dermatitisRosacea
| Precautions | Systemic absorption may cause reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, hyperglycemia, and glucosuria., Prolonged use may produce atrophy of skin, striae, and telangiectasias., Not for ophthalmic use., May mask or exacerbate infections. |
| Food/Dietary | No significant food interactions. Systemic absorption is negligible with topical use; however, if ingested accidentally, no specific dietary restrictions are needed. |
Loading safety data…
| Breastfeeding | Hydrocortisone valerate is minimally absorbed systemically after topical application. However, apply to smallest area for shortest duration to minimize infant exposure. Avoid application to breast area to prevent direct infant contact. |
| Lactation Rating | L2 (Safer) – limited systemic absorption, but caution advised. |
| Teratogenic Risk | Topical corticosteroids like hydrocortisone valerate are generally considered low risk for teratogenicity. However, systemic absorption may increase the risk of orofacial clefts in the first trimester with prolonged use of high potency corticosteroids. Use during pregnancy should be limited to low potency preparations for shortest duration; no specific fetal risks are established for hydrocortisone valerate. |
| Fetal Monitoring | Monitor for signs of maternal adrenal suppression (e.g., fatigue, hypotension) and fetal growth if used extensively. Observe infant for growth retardation or adrenal suppression if maternal use is prolonged or high dose. |
| Fertility Effects | No known effects on fertility in humans. Animal studies with corticosteroids have shown reduced fertility at high doses, but relevance to topical hydrocortisone valerate is minimal due to low systemic absorption. |
| Clinical Pearls | Hydrocortisone valerate is a moderately potent topical corticosteroid (class IV). Use for short-term treatment of corticosteroid-responsive dermatoses; avoid prolonged use, especially on face, intertriginous areas, and under occlusive dressings to minimize atrophy and systemic absorption. Limit to ≤50 g/week in adults. |
| Patient Advice | Apply a thin layer to affected skin only, usually twice daily. · Do not use on face, groin, or armpits unless directed by your doctor. · Avoid covering the treated area with bandages or wraps unless instructed. · Wash hands after application unless treating hands. · Do not use for more than 2 weeks continuously without re-evaluation. · Stop use and inform your doctor if irritation, infection, or worsening occurs. |